Published January 13, 2025
| Version v1
Journal article
Open
LC-MS/MS-based proteomics and metabolomics of HCT-116 colorectal cancer cells: A potential anticancer activity of atorvastatin
Authors/Creators
- 1. Jordan University of Science and Technology, Irbid, Jordan
- 2. University of Nottingham, Nottingham, United Kingdom|New York University Abu Dhabi (NYUAD), Abu Dhabi, United Arab Emirates
- 3. The University of Jordan, Amman, Jordan
Description
Colorectal cancer (CRC) is the third most prevalent tumor in men, the second most common in women, and the fourth leading cause of mortality worldwide. Statins reduce cholesterol levels by hampering the function of 3-hydroxy-3-methyl-glutaryl-CoA reductase enzymes in cholesterol synthesis. Strains have shown anticancer effects against CRC. However, statins' anticancer mechanism is yet unknown. Liquid chromatography–mass spectrometry (LC–MS)-based untargeted metabolomics and proteomics were employed to study statins' effects on CRC using the CRC cell line HCT-116. These approaches were utilized to identify potential underlying metabolic pathways and proteins altered in atorvastatin (a statin)-treated HCT-116 cells. Compared to the control, atorvastatin significantly altered numerous metabolites in HCT-116 cells, including a reduction in the levels of decanoylcarnitine and octanoyl-L-carnitine and in the biosynthesis and metabolism of amino acids like alanine and citrate cycle. Proteomic study showed that atorvastatin-treated HCT-116 cells expressed 127 proteins differently from controls. Novel findings were among them, such as centromere-associated protein E, cytochrome c oxidase subunit 6A1 mitochondrial, and hyaluronan synthase 1. The findings indicate that atorvastatin may have potential anticancer characteristics and highlight the essential role metabolomics and proteomics to understand complex metabolic pathways and proteins relevant to cancer and develop novel treatment targets.
Files
PHAR_article_138515.pdf
Files
(1.8 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:b22bd8f7948a87ff71f97f7c59c6f385
|
1.7 MB | Preview Download |
|
md5:99b6099861eda58137ce5c66a51c1797
|
138.5 kB | Preview Download |
Additional details
References
- Al-Saafin BA, Al-Bakri AG, Abdelrazig S, Dahabiyeh LA (2023) Investigating the effect of the probiotic Lactobacillus plantarum and the prebiotic fructooligosaccharides on Pseudomonas aeruginosa metabolome, virulence factors and biofilm formation as potential quorum sensing inhibitors. Microbial Pathogenesis 177: 106057. https://doi.org/10.1016/j.micpath.2023.106057
- Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P (2000) Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. Journal of Biological Chemistry 275: 30451–30457. https://doi.org/10.1074/jbc.M003469200
- Batth TS, Tollenaere MX, Rüther P, Gonzalez-Franquesa A, Prabhakar BS, Bekker-Jensen S, Deshmukh AS, Olsen JV (2019) Protein Aggregation Capture on Microparticles Enables Multipurpose Proteomics Sample Preparation. Molecular & Cellular Proteomics 18: 1027–1035. https://doi.org/10.1074/mcp.TIR118.001270
- Buccioli G, Testa C, Jacchetti E, Pinoli P, Carelli S, Ceri S, Raimondi MT (2024) The molecular basis of the anticancer effect of statins. Scientific Reports 14: 20298. https://doi.org/10.1038/s41598-024-71240-6
- Cekanova M, Lee SH, Donnell RL, Sukhthankar M, Eling TE, Fischer SM, Baek SJ (2009) Nonsteroidal anti-inflammatory drug-activated gene-1 expression inhibits urethane-induced pulmonary tumorigenesis in transgenic mice. Cancer Prevention Research (Phila) 2: 450–458. https://doi.org/10.1158/1940-6207.Capr-09-0057
- Chen B, Zhang M, Xing D, Feng Y (2017) Atorvastatin enhances radiosensitivity in hypoxia-induced prostate cancer cells related with HIF-1α inhibition. Bioscience reports 37: BSR20170340. https://doi.org/10.1042/BSR20170340
- Choi YK, Park KG (2018) Targeting Glutamine Metabolism for Cancer Treatment. Biomol Ther (Seoul) 26: 19–28. https://doi.org/10.4062/biomolther.2017.178
- Chung V, Heath EI, Schelman WR, Johnson BM, Kirby LC, Lynch KM, Botbyl JD, Lampkin TA, Holen KD (2012) First-time-in-human study of GSK923295, a novel antimitotic inhibitor of centromere-associated protein E (CENP-E), in patients with refractory cancer. Cancer chemotherapy and pharmacology 69: 733–741. https://doi.org/10.1007/s00280-011-1756-z
- Dahabiyeh LA, Hourani W, Darwish W, Hudaib F, Abu-Irmaileh B, Deb PK, Venugopala KN, Mohanlall V, Abu-Dahab R, Semreen MH, Bustanji Y (2022) Molecular and metabolic alterations of 2,3-dihydroquinazolin-4(1H)-one derivatives in prostate cancer cell lines. Scientific Reports 12(1): 21599. https://doi.org/10.1038/s41598-022-26148-4
- Dahabiyeh LA, Hudaib F, Hourani W, Darwish W, Abu-Irmaileh B, Deb PK, Venugopala KN, Mohanlall V, Chandrashekharappa S, Abu-Dahab R, Semreen MH, Bustanji Y (2023a) Mass spectrometry-based metabolomics approach and in vitro assays revealed promising role of 2,3-dihydroquinazolin-4(1H)-one derivatives against colorectal cancer cell lines. European Journal of Pharmaceutical Sciences 182: 106378. https://doi.org/10.1016/j.ejps.2023.106378
- Dahabiyeh LA, Mahmoud NN, Al-Natour MA, Safo L, Kim DH, Khalil EA, Abu-Dahab R (2021) Phospholipid-Gold Nanorods Induce Energy Crisis in MCF-7 Cells: Cytotoxicity Evaluation Using LC-MS-Based Metabolomics Approach. Biomolecules 11(3): 364. https://doi.org/10.3390/biom11030364
- Dahabiyeh LA, Nimer RM (2023) Metabolomics: A Pipeline for Biomarker Discovery in Genetic Diseases. In: Abdel Rahman AM (Ed.) Clinical Metabolomics Applications in Genetic Diseases. Springer Nature Singapore, Singapore, 43–69. https://doi.org/10.1007/978-981-99-5162-8_3
- Dahabiyeh LA, Nimer RM, Sumaily KM, Alabdaljabar MS, Jacob M, Sabi EM, Hussein MH, Abdel Rahman A (2023b) Metabolomics profiling distinctively identified end-stage renal disease patients from chronic kidney disease patients. Scientific Reports 13: 6161. https://doi.org/10.1038/s41598-023-33377-8
- Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. The Lancet 394: 1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0
- Dobrzycka M, Spychalski P, Łachiński AJ, Kobiela P, Jędrusik P, Kobiela J (2020) Statins and colorectal cancer–a systematic review. Experimental and Clinical Endocrinology & Diabetes 128: 255–262. https://doi.org/10.1055/a-0668-5692
- Dorsch M, Kowalczyk M, Planque M, Heilmann G, Urban S, Dujardin P, Forster J, Ueffing K, Nothdurft S, Oeck S (2021) Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis. Cell Reports 37(8): 110056. https://doi.org/10.1016/j.celrep.2021.110056
- Dulak J, Józkowicz A (2005) Anti-angiogenic and anti-inflammatory effects of statins: relevance to anti-cancer therapy. Current Cancer Drug Targets 5: 579–594. https://doi.org/10.2174/156800905774932824
- El-Arabey AA, Salama SA, Abd-Allah AR (2018) CENP-E as a target for cancer therapy: Where are we now? Life Sciences 208: 192–200. https://doi.org/10.1016/j.lfs.2018.07.037
- Fatehi Hassanabad A (2019) Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms. Transl Lung Cancer Res 8: 692–699. https://doi.org/10.21037/tlcr.2019.09.08
- Fernandes Silva L, Ravi R, Vangipurapu J, Laakso M (2022) Metabolite Signature of Simvastatin Treatment Involves Multiple Metabolic Pathways. Metabolites 12(8): 753. https://doi.org/10.3390/metabo12080753
- Fliedner SM, Engel T, Lendvai NK, Shankavaram U, Nölting S, Wesley R, Elkahloun AG, Ungefroren H, Oldoerp A, Lampert G (2014) Anti-Cancer Potential of MAPK Pathway Inhibition in Paragangliomas–Effect of Different Statins on Mouse Pheochromocytoma Cells. PLoS ONE 9: e97712. https://doi.org/10.1371/journal.pone.0097712
- Fujiwara D, Tsubaki M, Takeda T, Tomonari Y, Koumoto Y-i, Sakaguchi K, Nishida S (2017) Statins induce apoptosis through inhibition of Ras signaling pathways and enhancement of Bim and p27 expression in human hematopoietic tumor cells. Tumor Biology 39: 1010428317734947. https://doi.org/10.1177/1010428317734947
- Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144: 646–674. https://doi.org/10.1016/j.cell.2011.02.013
- Hijazi DM, Dahabiyeh LA, Abdelrazig S, Alqudah DA, Al-Bakri AG (2023) Micafungin effect on Pseudomonas aeruginosa metabolome, virulence and biofilm: potential quorum sensing inhibitor. AMB Express 13: 20. https://doi.org/10.1186/s13568-023-01523-0
- Jiang W, Hu J-W, He X-R, Jin W-L, He X-Y (2021) Statins: a repurposed drug to fight cancer. Journal of Experimental & Clinical Cancer Research 40: 241. https://doi.org/10.1186/s13046-021-02041-2
- Jones HM, Fang Z, Sun W, Clark LH, Stine JE, Tran A-Q, Sullivan SA, Gilliam TP, Zhou C, Bae-Jump VL (2017) Atorvastatin exhibits anti-tumorigenic and anti-metastatic effects in ovarian cancer in vitro. American Journal of Cancer Research 7: 2478.
- Kheirelseid EA, Miller N, Kerin MJ (2013) Molecular biology of colorectal cancer: Review of the Literature 3: 72–80. https://doi.org/10.4236/ajmb.2013.32010
- Kramer MW, Escudero DO, Lokeshwar SD, Golshani R, Ekwenna OO, Acosta K, Merseburger AS, Soloway M, Lokeshwar VB (2011) Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer 117: 1197–1209. https://doi.org/10.1002/cncr.25565
- Lee SJ, Lee I, Lee J, Park C, Kang WK (2014) Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. British Journal of Cancer 111: 497–505. https://doi.org/10.1038/bjc.2014.283
- Liang J, Tian C, Liu L, Zeng X, Zhang Y (2024) Targeting CENP-E augments immunotherapy in non-small cell lung cancer via stabilizing PD-L1. International Immunopharmacology 126: 111294. https://doi.org/10.1016/j.intimp.2023.111294
- Liang Y, Ahmed M, Guo H, Soares F, Hua JT, Gao S, Lu C, Poon C, Han W, Langstein J (2017) LSD1-mediated epigenetic reprogramming drives CENPE expression and prostate cancer progression. Cancer Research 77: 5479–5490. https://doi.org/10.1158/0008-5472.CAN-17-0496
- Liu W, Wang Q, Chang J (2019) Global metabolomic profiling of trastuzumab resistant gastric cancer cells reveals major metabolic pathways and metabolic signatures based on UHPLC-Q exactive-MS/MS. RSC Advances 9: 41192–41208. https://doi.org/10.1039/c9ra06607a
- Lock RB, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gorlick R, Kolb EA (2012) Initial testing of the CENP‐E inhibitor GSK923295A by the pediatric preclinical testing program. Pediatric Blood & Cancer 58: 916–923. https://doi.org/10.1002/pbc.23176
- Longo N, Frigeni M, Pasquali M (2016) Carnitine transport and fatty acid oxidation. Biochimica et Biophysica Acta (BBA) 1863: 2422–2435. https://doi.org/10.1016/j.bbamcr.2016.01.023
- Lukarska M, Palencia A (2020) Chapter Eleven - Aminoacyl-tRNA synthetases as drug targets. In: Ribas de Pouplana L, Kaguni LS (Eds) The Enzymes. Academic Press, 321–350. https://doi.org/10.1016/bs.enz.2020.07.001
- Luo P, Yan H, Du J, Chen X, Shao J, Zhang Y, Xu Z, Jin Y, Lin N, Yang B, He Q (2021) PLK1 (polo like kinase 1)-dependent autophagy facilitates gefitinib-induced hepatotoxicity by degrading COX6A1 (cytochrome c oxidase subunit 6A1). Autophagy 17: 3221–3237. https://doi.org/10.1080/15548627.2020.1851492
- Majidi A, Na R, Jordan SJ, De Fazio A, Webb PM, Group OS (2021) Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. International Journal of Cancer 148: 1608–1615. https://doi.org/10.1002/ijc.33333
- Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E, Rodriguez Yoldi MJ (2017) Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer. International Journal of Molecular Sciences 18(1): 197. https://doi.org/10.3390/ijms18010197
- McAtee CO, Barycki JJ, Simpson MA (2014) Emerging roles for hyaluronidase in cancer metastasis and therapy. Advances in Cancer Research 123: 1–34. https://doi.org/10.1016/b978-0-12-800092-2.00001-0.
- McGregor GH, Campbell AD, Fey SK, Tumanov S, Sumpton D, Blanco GR, Mackay G, Nixon C, Vazquez A, Sansom OJ (2020) Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic antitumor response. Cancer Research 80: 175–188. https://doi.org/10.1158/0008-5472.CAN-19-0644
- Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD (2019) PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Research 47: D419-D426. https://doi.org/10.1093/nar/gky1038
- Min Y, Liu Z, Wei Z, Li R, Jin J, Zhang Y, Peng X (2022) Association between Statin Use and Survival in Cancer Patients with Brain Metastasis: Retrospective Analysis from the Chinese Population. Pharmaceuticals 15: 1474. https://doi.org/10.3390/ph15121474
- Modi A, Dwivedi S, Roy D, Khokhar M, Purohit P, Vishnoi J, Pareek P, Sharma S, Sharma P, Misra S (2019) Growth differentiation factor 15 and its role in carcinogenesis: an update. Growth Factors 37: 190–207. https://doi.org/10.1080/08977194.2019.1685988
- Mozolewska P, Duzowska K, Pakiet A, Mika A, Śledziński T (2020) Inhibitors of fatty acid synthesis and oxidation as potential anticancer agents in colorectal cancer treatment. Anticancer Research 40: 4843–4856. https://doi.org/10.21873/anticanres.14487
- Nakashima Y, Miyagi-Shiohira C, Noguchi H, Omasa T (2018) Atorvastatin Inhibits the HIF1α-PPAR Axis, Which Is Essential for Maintaining the Function of Human Induced Pluripotent Stem Cells. Molecular Therapy 26: 1715–1734. https://doi.org/10.1016/j.ymthe.2018.06.005
- Nikitovic D, Tzardi M, Berdiaki A, Tsatsakis A, Tzanakakis GN (2015) Cancer microenvironment and inflammation: role of hyaluronan. Frontiers in Immunology 6: 169. https://doi.org/10.3389/fimmu.2015.00169
- Nimer RM, Alfaqih MA, Shehabat ER, Mujammami M, Abdel Rahman AM (2023) Label-free quantitative proteomics analysis for type 2 diabetes mellitus early diagnostic marker discovery using data-independent acquisition mass spectrometry (DIA-MS). Scientific Reports 13: 20880. https://doi.org/10.1038/s41598-023-48185-3
- Pang Z, Chong J, Zhou G, de Lima Morais DA, Chang L, Barrette M, Gauthier C, Jacques P-É, Li S, Xia J (2021) MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. Nucleic Acids Research 49: W388-W396. https://doi.org/10.1093/nar/gkab382
- Patel S, Turner PR, Stubberfield C, Barry E, Rohlff CR, Stamps A, McKenzie E, Young K, Tyson K, Terrett J, Box G, Eccles S, Page MJ (2002) Hyaluronidase gene profiling and role of hyal-1 overexpression in an orthotopic model of prostate cancer. International Journal of Cancer 97: 416–424. https://doi.org/10.1002/ijc.1638
- Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, Zhang A (2023) Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduction and Targeted Therapy 8: 132. https://doi.org/10.1038/s41392-023-01399-3
- Roth BD (2002) 1 The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Progress in medicinal chemistry 40: 1–22. https://doi.org/10.1016/S0079-6468(08)70080-8
- Shaghaghi Z, Alvandi M, Farzipour S, Dehbanpour MR, Nosrati S (2022) A review of effects of atorvastatin in cancer therapy. Medical Oncology 40: 27. https://doi.org/10.1007/s12032-022-01892-9
- Siiskonen H, Oikari S, Pasonen-Seppänen S, Rilla K (2015) Hyaluronan synthase 1: a mysterious enzyme with unexpected functions. Frontiers in Immunology 6: 43. https://doi.org/10.3389/fimmu.2015.00043
- Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, Fan TW-M, Fiehn O, Goodacre R, Griffin JL (2007) Proposed minimum reporting standards for chemical analysis: chemical analysis working group (CAWG) metabolomics standards initiative (MSI). Metabolomics 3: 211–221. https://doi.org/10.1007/s11306-007-0082-2
- Sung JJY, Lau JYW, Goh KL, Leung WK (2005) Increasing incidence of colorectal cancer in Asia: implications for screening. The Lancet Oncology 6: 871–876. https://doi.org/10.1016/S1470-2045(05)70422-8
- Sung Y, Yoon I, Han JM, Kim S (2022) Functional and pathologic association of aminoacyl-tRNA synthetases with cancer. Experimental & Molecular Medicine 54: 553–566. https://doi.org/10.1038/s12276-022-00765-5
- Takada K, Shimokawa M, Takamori S, Shimamatsu S, Hirai F, Tagawa T, Okamoto T, Hamatake M, Tsuchiya-Kawano Y, Otsubo K (2022) A propensity score-matched analysis of the impact of statin therapy on the outcomes of patients with non-small-cell lung cancer receiving anti-PD-1 monotherapy: a multicenter retrospective study. BMC Cancer 22: 503. https://doi.org/10.1186/s12885-022-09385-8
- Tyers M, Mann M (2003) From genomics to proteomics. Nature 422: 193–197. https://doi.org/10.1038/nature01510
- Walther U, Emmrich K, Ramer R, Mittag N, Hinz B (2016) Lovastatin lactone elicits human lung cancer cell apoptosis via a COX-2/PPARγ-dependent pathway. Oncotarget 7: 10345. https://doi.org/10.18632/oncotarget.7213
- Wang X, Baek SJ, Eling TE (2013) The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer. Biochemical Pharmacology 85: 597–606. https://doi.org/10.1016/j.bcp.2012.11.025
- Warita T, Irie N, Zhou Y, Tashiro J, Sugiura A, Oltvai ZN, Warita K (2023) Alterations in the omics profiles in mevalonate pathway-inhibited cancer cells. Life Sciences 312: 121249. https://doi.org/10.1016/j.lfs.2022.121249
- Wood KW, Lad L, Luo L, Qian X, Knight SD, Nevins N, Brejc K, Sutton D, Gilmartin AG, Chua PR, Desai R, Schauer SP, McNulty DE, Annan RS, Belmont LD, Garcia C, Lee Y, Diamond MA, Faucette LF, Giardiniere M, Zhang S, Sun CM, Vidal JD, Lichtsteiner S, Cornwell WD, Greshock JD, Wooster RF, Finer JT, Copeland RA, Huang PS, Morgans DJ Jr., Dhanak D, Bergnes G, Sakowicz R, Jackson JR (2010) Antitumor activity of an allosteric inhibitor of centromere-associated protein-E. Proceedings of the National Academy of Sciences (PNAS) 107: 5839–5844. https://doi.org/10.1073/pnas.0915068107
- Worley B, Powers R (2013) Multivariate analysis in metabolomics. Current Metabolomics 1: 92–107. https://doi.org/10.2174/2213235X11301010092
- Xi Y, Xu P (2021) Global colorectal cancer burden in 2020 and projections to 2040. Translational Oncology 14: 101174. https://doi.org/10.1016/j.tranon.2021.101174
- Yang H, Filipovic Z, Brown D, Breit SN, Vassilev LT (2003) Macrophage inhibitory cytokine-1: a novel biomarker for p53 pathway activation. Molecular Cancer Therapeutics 2: 1023–1029.
- Yin P, Wan D, Zhao C, Chen J, Zhao X, Wang W, Lu X, Yang S, Gu J, Xu G (2009) A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. Molecular BioSystems 5: 868–876. https://doi.org/10.1039/B820224A
- Yokohama K, Fukunishi S, Ii M, Nakamura K, Ohama H, Tsuchimoto Y, Asai A, Tsuda Y, Higuchi K (2016) Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice. International Journal of Molecular Medicine 38: 1499–1506. https://doi.org/10.3892/ijmm.2016.2766
- Yuan Q, Dong CD, Ge Y, Chen X, Li Z, Li X, Lu Q, Peng F, Wu X, Zhao J, Liu K (2019) Proteome and phosphoproteome reveal mechanisms of action of atorvastatin against esophageal squamous cell carcinoma. Aging (Albany NY) 11: 9530–9543. https://doi.org/10.18632/aging.102402
- Zafari N, Bathaei P, Velayati M, Khojasteh-Leylakoohi F, Khazaei M, Fiuji H, Nassiri M, Hassanian SM, Ferns GA, Nazari E, Avan A (2023) Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for colorectal cancer. Computers in Biology and Medicine 155: 106639. https://doi.org/10.1016/j.compbiomed.2023.106639
- Zaky MY, Fan C, Zhang H, Sun X-F (2023) Unraveling the anticancer potential of statins: Mechanisms and clinical significance. Cancers 15: 4787. https://doi.org/10.3390/cancers15194787
- Zhan X, Long Y, Lu M (2018) Exploration of variations in proteome and metabolome for predictive diagnostics and personalized treatment algorithms: Innovative approach and examples for potential clinical application. Journal of Proteomics 188: 30–40. https://doi.org/10.1016/j.jprot.2017.08.020